Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model

Background: Symptom relief for the duration of 24 hours after treatment would benefit patients with allergic conjunctivitis. Objective: To compare the safety and efficacy of olopatadine 0.77% with vehicle or olopatadine 0.2% in patients with allergic conjunctivitis in a conjunctival allergen-challenge clinical study. Patients and methods: In this Phase III, multicenter, double-masked, parallel-group, randomized trial, patients with allergic...